Denali Therapeutics reported robust financial performance for Q2 2026, exceeding expectations. The strong results were primarily driven by the successful market introduction of its new drug, AVLAYAH™.
Denali Therapeutics Posts Strong Q2 2026 Results on AVLAYAH™ Launch
|1 min read
DenaliTherapeuticsPharmaceuticalsEarningsBiotechQ22026